Arca
Skip to content
Tools
Tools

-tug

A full-length monoclonal antibody whose constant region is unchanged from nature. Part of the scheme WHO adopted in 2021 to replace -mab; a drug or toxin attached to it is named in a second word.

  • Drugs ending in -tug: 91
  • Approved somewhere: 0
  • With a US drug page: 1

What it means

Stem from WHO's stem book, 2024; description by Arca
Stem
-tug
Class
Unmodified full-length antibodies (2021 naming scheme)
Most common targets
ITGB6 (2), IGF1R (1), CXCL8 (1), Fucosyl-GM1 (1), CD274 (1), IL6 (1)

Drugs that carry it

Approved and clinical-stage drugs in ChEMBL whose names ending in -tug, matched by spelling; those with a US drug page link to it.
Acts on
VeligrotugPhase 2IGF1RInsulin-like growth factor I receptor antagonist
Becotatug vedotinPhase 3——
BelrestotugPhase 3——
ErsodetugPhase 3——
GimistotugPhase 3——
RemternetugPhase 3——
Sigvotatug vedotinPhase 3ITGB6Integrin beta-6 binding agent
SiltartoxatugPhase 3——
AdakitugPhase 2CXCL8Interleukin-8 inhibitor
AldastotugPhase 2——
AletekitugPhase 2——
AlextatugPhase 2——
AmlenetugPhase 2——
AtigotatugPhase 2Fucosyl-GM1Fucosyl-GM1 binding agent
AzirkitugPhase 2——
BecotatugPhase 2——
BosakitugPhase 2——
CalotatugPhase 2——
Calotatug ginistinagPhase 2——
CalpurbatugPhase 2——
CanrivitugPhase 2——
CasdozokitugPhase 2——
CiletatugPhase 2——
Ciletatug vedotinPhase 2——
DanburstotugPhase 2CD274Programmed cell death 1 ligand 1 inhibitor
DargistotugPhase 2——
DenikitugPhase 2——
DevextinetugPhase 2——
DibotatugPhase 2——
DuvakitugPhase 2——
EclutatugPhase 2——
EmiltatugPhase 2——
Emiltatug ledadotinPhase 2——
EmunkitugPhase 2——
EvalstotugPhase 2——
FalbikitugPhase 2——
FelmetatugPhase 2——
Felmetatug vedotinPhase 2——
FirastotugPhase 2——
GacovetugPhase 2——
IbentatugPhase 2——
IndemakitugPhase 2——
LafuvitugPhase 2——
LancastotugPhase 2——
LanerkitugPhase 2——
LibevitugPhase 2——
LumrotatugPhase 2——
MisitatugPhase 2——
Misitatug blivedotinPhase 2——
MuzastotugPhase 2——
NebokitugPhase 2——
NelistotugPhase 2——
NezutatugPhase 2——
NisevokitugPhase 2——
NuvustotugPhase 2——
OberotatugPhase 2——
Oberotatug ravtansinePhase 2——
OcankitugPhase 2——
OlintatugPhase 2——
Olintatug tesirinePhase 2——
OmectatugPhase 2——
PacibekitugPhase 2IL6Interleukin-6 inhibitor
PuxitatugPhase 2——
Puxitatug samrotecanPhase 2——
RaludotatugPhase 2——
Raludotatug deruxtecanPhase 2——
RalzapastotugPhase 2——
RemzistotugPhase 2——
SabirnetugPhase 2——
SamatatugPhase 2——
Samatatug zovodotinPhase 2——
SeniprutugPhase 2——
SigvotatugPhase 2ITGB6Integrin beta-6 inhibitor
SolnerstotugPhase 2——
SolrikitugPhase 2——
SonesitatugPhase 2——
Sonesitatug vedotinPhase 2——
TizetatugPhase 2——
Tizetatug rezetecanPhase 2——
TraxivitugPhase 2——
VerekitugPhase 2——
VopikitugPhase 2——
ZovostotugPhase 2——
BudoprutugPhase 1——
EtalanetugPhase 1——
GorivitugPhase 1——
ImzokitugPhase 1——
LunlekitugPhase 1——
RilogrotugPhase 1——
SuvemcitugPhase 1——
VilamakitugPhase 1——

Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.